Shares of Pacira BioSciences PCRX gained 11.1% on Friday after the company shared better-than-expected preliminary fourth-quarter 2024 sales figures for its marketed products. Additionally ...

(RTTNews) - Optinose, Inc. (OPTN), a pharmaceutical company focused on ear, nose and throat or ENT and allergy, announced Wednesday preliminary XHANCE (fluticasone propionate) net product revenue ...

TreeHouse, a huge supplier of private label food and beverages, also reaffirmed its FY24 guidance, including the expectation of sequential improvement in volume growth and profit margin in Q4. THS ...

We recorded net product sales of approximately $36M in Q4 and $42M for full year 2024…We are excited by the initial impact of Ohtuvayre and look forward to building on this momentum in 2025.” ...

QAPs revenues of $1,698,335 were up 42% from Q4 2023 (2023 - $1,195,231), due to strong performance from our PTDx ®, PROCEEDx ® and REDx™ QAPs products. Revenue from royalties were $123,603 (2023 - ...

The FDA's rule proposal would, if finalized, require U.S. food manufacturers to add a front-of-package (FOP) nutrition label on most ... manufacturers reformulate products to be healthier in ...

The company expects Briumvi U.S. net product revenue of $103.6 million for the fourth quarter, and $310 million for the full year 2024. Looking forward, TG anticipates total global revenue of ...

Q4 gross margin percentage was 55%, up from 33% in 2023, primarily due to a more favourable Antigen product mix, increased QAPs revenues, and a lower rate of Antigen batch failures this year.

Business and Customer Highlights In Q4, YuJa expanded its global footprint ... Higher Ground 2024 Conference in the fourth quarter. Product Updates Span YuJa’s Portfolio YuJa made many updates ...

The company estimates Q4 product revenue between $9.0 million-$9.2 million vs. consensus of $9.45M, representing 22-25% growth compared to Q4 2023. Full-year 2024 product revenue is expected to ...